Resection without macroscopic and microscopic residual tumor is the prerequisite for achieving cure in localized esophago-gastric cancer (EGC). But even after R0 resection with adequate lymphadenectomy, the overall prognosis of resected EGC is critical, because minimal residual disease may cause relapse which ultimately leads to death. To prevent recurrence and help patients to survive, perioperative treatment has been studied in randomized, controlled trials and has become standard of care. While Asians prefer postoperative (adjuvant) chemotherapy and some US centers are in favor of adjuvant chemoradiotherapy according to the Intergroup 0116 study, the majority of European, Australian and Canadian centers recommend perioperative chemotherapy or preoperative chemoradiation, depending on the exact localization and the histological subtype of the tumor [1, 2] .
Despite radical resection and perioperative treatment, 50%-65% of patients with stage II and III EGC recur and die within 5 years. Obviously, in these patients chemotherapy was unable to eradicate minimal residual disease. On the other hand, between 25% and 50% of patients do recur after surgery alone, indicating that chemotherapy is not needed in a considerable number of patients [3] [4] [5] . In brief, unnecessary as well as ineffective treatments are two unresolved issues in EGC.
Biomarker testing has become an integral part of research in oncology. Prognostic biomarkers are investigated to clarify the need for more or less treatment. Predictive biomarkers are needed to select the right drugs for a specific patient. This sounds easier than it is. Postoperative nomograms and modified pathological staging systems may provide more robust prognostic information than classical TNM staging in localized EGC [6, 7] . But the major problem of systems based on the analysis of resection specimens is that prognostic information is unavailable at the crucial time point of treatment planning. Second, unfavorable prognostic biomarkers do not necessarily indicate whether patients will benefit from more intensive treatment and which particular treatment could improve the prognosis. In brief, we do not yet have sufficiently validated prognostic biomarkers in EGC and we completely lack predictive markers in the setting of localized disease eligible for preoperative chemotherapy.
Several hypothesis-generating studies have been published on biomarkers potentially predicting the sensitivity to chemotherapy in EGC. Expression and polymorphisms of 5-fluorouracil (5-FU) targets and platinum detoxification enzymes are among the most frequently investigated molecules. But study results from different groups were often conflicting and inconsistent [8, 9] . Microsatellite instability may describe a distinct biological subgroup of EGC associated with a different prognosis and response to chemotherapy, but findings are not yet robust [10] .
One of the most promising hypotheses was the potential association of HER2 amplification with a benefit from epirubicin-containing chemotherapy. As elaborated by Okines et al. in their article, in breast cancer HER2 amplification is a potential predictive biomarker of epirubicin sensitivity, probably due to co-amplification with the topoisomerase IIα gene, located close to HER2 on chromosome 17q21 [11] . This prompted the authors to investigate this question in EGC.
The authors sampled tumor material from the prospective, randomized, controlled, MAGIC trial. This trial randomly assigned patients with localized EGC, clinical stage II and III, to receive surgery alone or surgery with perioperative epirubicin, cisplatin and 5-FU [3] . Perioperative chemotherapy led to a meaningful and statistically significant survival benefit. Paraffin-embedded tumor blocks from the diagnostic biopsy, resection specimen or both were received from 415 of 503 patients. Tissue microarrays (TMAs) were constructed. HER2 protein expression was assessed by immunohistochemistry. In addition, gene amplification was investigated using bright-field dual in situ-hybridization. The HER2 positivity rate was 10.9% in the whole cohort with a concordance between HER2 protein expression and gene amplification of 96%. A major result of this study was that HER2 was not found to be prognostic. Even more important, pretreatment biopsies did not indicate an enhanced benefit for HER2 positive tumors from epirubicincontaining chemotherapy [11] .
Therefore, the principal hypothesis of this study, which was that HER2 expression may predict the benefit of chemotherapy, could not be verified. One major problem of the analysis may be the limited power of testing for heterogeneity, given that in only 15 patients a positive HER2 status was assessed from pre-treatment biopsies. Another potential problem is the doubtful contribution of epirubicin to the benefit of perioperative chemotherapy of EGC in general [11] . Of note, colleagues from France who conducted a trial in parallel to the UK MAGIC study used cisplatin and 5-FU (without epirubicin!) and came up with the same hazard ratio in favor of perioperative chemotherapy versus surgery alone [5] . A recently presented adjuvant study from the United States found no difference in survival of patients treated with adjuvant radiation combined with 5-FU versus adjuvant radiation combined with epirubicin, cisplatin and 5-FU [12] . Moreover, a systematic review indicating that epirubicin may be effective in advanced gastric cancer has been criticized for methodological drawbacks [13] . If gastric cancer is only moderately sensitive to anthracyclines in general, any predictive marker for anthracycline sensitivity will eventually fail.
Almost 20 years of research on HER2-expression in EGC has generated a plethora of results which can be summarized as follows [14] : HER2 overexpression correlates significantly with HER2-gene amplification; HER2 is heterogeneously distributed in the primary tumor as well as in metastases; and finally, HER2 is more prevalent in proximal and intestinal type gastric cancers, respectively. It is currently impossible to provide definitive conclusions from the literature on the association of HER2-expression with patient survival, local tumor growth (T-category), nodal spread (N-category) or tumor stage according to Unio Internationale Contra Cancrum (UICC) [14] .
The assessment of HER2 overexpression is more complicated in EGC compared with breast cancer. It necessitated the development of a novel scoring system, which is different from the breast cancer scoring [15] . Gastric cancer cells more commonly harbor basolateral expression and rarely circumferential HER2-staining [15, 16] . The gastric cancer scoring-system takes into account the unique expression patterns (including heterogeneity) of HER2 in EGC and increased the comparability of study results obtained from different regions (Asian vs. European/North-American). However, a major problem remained unanswered, i.e. which effect perioperative treatment has on HER2 expression and hence its correlation with prognosis. Okines et al. are among the first to address systematically this important issue, and provide evidence that HER2 has no prognostic or predictive value in patients receiving perioperative chemotherapy in the MAGIC study [11] . In this respect, European GC study cohorts are different from many Asian study cohorts, where adjuvant chemotherapy with fluoropyrimidines for stage II and III EGCs has been standard of care for a longer period of time than in Europe. This may have had ill-defined impacts on studies, evaluating the correlation between HER2-expression and prognosis. Why is the correlation between tumor HER2-expression and patient survival inconsistent among different studies? Apart from sometimes ill-defined confounding variables such as different treatment modalities (e.g. with and without adjuvant/perioperative chemotherapy or radiation), it has to be kept in mind that intestinal and non-intestinal type EGCs show significant differences with regard to HER2 expression as well as prognosis [14] . Statistical analyses which do not take into account these facts may generate misleading results. The seemingly prognostic influence of HER2 may also be related to the phenotype (i.e. intestinal versus. diffuse). However, given the overall low prevalence of HER2, subgroup analyses often suffer from the small patient numbers, and meta-analyses are hampered by the different staining and scoring systems used in the diverse studies [14, 17] . This problem is illustrated by the study of Okines et al. [11] . They confirm the relatively low prevalence of HER2 overexpression in a large group of 415 EGC patients. Two recently published reviews on the overall prevalence of HER2-expression reported on prevalence ranging from 4.4% to 53.4% [14, 17] . These differences are certainly due to different scoring systems and different staining protocols. More recent studies using the gastric cancer scoring-system (immunohistochemistry coupled with in situ hybridization) harvest smaller differences, commonly ranging between 5% and 29% HER2 positivity [18] . Given the low prevalence of HER2 overexpression in EGC, correct classification of EGC patients as HER2-positive ornegative is becoming a major issue for the resulting medical treatment, and hence particular attention should be paid to study conduction. Okines et al. used TMAs throughout their study, which were obtained from biopsies and resection specimens [11] . Our own previous studies have shown that the generation of TMAs in itself carries the risk of a sampling error [18] . The comparison of whole tissue sections with the corresponding TMAs, the latter generated from the same paraffin blocks used for the assessment of whole tissue sections, showed a false-negative rate of 24% and a falsepositive rate of 3% for TMAs [18] . Even sampling for the generation of TMAs carries the risk of a study bias and should be kept in mind. Okines et al. generated TMAs from biopsy and resection specimens [11] . The core cylinders collected from biopsies had a smaller diameter (0.5 mm) than those obtained from resection specimens (1.0 mm). This adds further risks of sampling errors and has to be considered, when interpreting their results.
HER2-expression in EGC teaches many lessons. Research carried out over a period of 20 years with different scoring systems limits the comparability of study results [14, 17] . This is further fraught with the risk of ill-defined therapy regimens and standards of care used in different parts of the World and different countries. Not all are clearly outlined in the publications. Complexity is increased by the heterogeneity of tissue samples used in the diverse studies (biopsy before or after therapy; resection specimens before or after chemotherapy or radiation) and different staining and scoring systems applied. Studies on HER2 in EGC underscore the importance of standardizing staining protocols, evaluation systems, study designs, study conduct and the plenty-full pitfalls, when standards are lacking. The only chance to advance the development of companion diagnostics and their translation into routine clinical practice is standardization.
What is the future of biomarker testing in EGC? HER2 highlights several major advancements and problems of targeted therapy and the development and validation of companion diagnostics. The ToGA study [19] has spurred an abundant and fruitful international research effort on HER2 in EGC, which is unlikely to have taken place without the results of the ToGA study. Searching the database www.ncbi.nlm.nih. gov/pubmed for the terms 'Her2', 'ErbB2', 'stomach', 'gastric' and 'cancer' generated 748 hits for the time period spanning 1986 through 2012. Between 1986 and 2011 the average number of publications was 17.6/year and increased during the last 3 years to 108.3/year (Figure 1 ). The expectation of improved patient outcomes significantly urges research on predictive and prognostic biomarkers. These have shown that (i) study populations are becoming increasingly heterogeneous with regard to oncological treatment protocols applied to individual patients and patient subgroups before study inclusion.
(ii) The number of patients available for studies on targeted therapeutics is small given the low prevalence of the target molecule in EGC subtypes (usually <20% of a tumor type). (iii) Cohorts of treatment naïve patients are becoming increasingly difficult to collect, particularly when perioperative and adjuvant (radio-) chemotherapy is standard of care. (4) National and international guidelines on cancer diagnosis and treatment do not specify the amount of tumor tissue necessary for reaching a diagnosis.
The diagnosis of cancer can be achieved on a fairly small amount of tissue. However, this amount may be unsuitable for the examination of prognostic or predictive biomarkers, as it carries the risk of sampling errors. The only way out of this quandary is an international effort aiming for a rigorous standardization of sampling procedures, thereby reducing the influence of confounding pre-analytical factors (including tissue sampling), standardization of analytical tests controlled by external quality assurance systems, standardization of scoring systems early in the development of companion diagnostics, and robust validation of the diagnostic algorithms by independent study cohorts [20] . These efforts reach beyond REMARK and STARD as we now need standards not only for reporting, but also for the conduct of these studies [20, 21] . 
